IMC Chicago’s Neurocrine Biosciences NBIX Stock Holding History

IMC Chicago’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,951	Closed	-$735K	–	6628
2026 Q1	$652K	Buy	+4,951	New	+$657K	﹤0.01%	3747

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

IMC Chicago's NBIX Position: Q2 2026 in Review

IMC Chicago sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 4,951 shares — an estimated $735K sold.

IMC Chicago first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $652K in Q1 2026. 481 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

IMC Chicago reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 4,951 Neurocrine Biosciences shares in Q2 2026, an estimated $735K.
IMC Chicago first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
IMC Chicago's Neurocrine Biosciences position peaked at $652K in Q1 2026.
481 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.